Literature DB >> 3740683

Confidence intervals for reporting results of clinical trials.

R Simon.   

Abstract

Tests of statistical significance are often used by investigators in reporting the results of clinical research. Although such tests are useful tools, the significance levels are not appropriate indices of the size or importance of differences in outcome between treatments. Lack of "statistical significance" can be misinterpreted in small studies as evidence that no important difference exists. Confidence intervals are important but underused supplements to tests of significance for reporting the results of clinical investigations. Their usefulness is discussed here, and formulas are presented for calculating confidence intervals with types of data commonly found in clinical trials.

Mesh:

Year:  1986        PMID: 3740683     DOI: 10.7326/0003-4819-105-3-429

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  64 in total

Review 1.  Biological interpretation of relative risk.

Authors:  S F Lanes
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  S J Veldhuyzen van Zanten; N J Talley; P Bytzer; K B Klein; P J Whorwell; A R Zinsmeister
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

3.  Reporting and concordance of methodologic criteria between abstracts and articles in diagnostic test studies.

Authors:  C A Estrada; R M Bloch; D Antonacci; L L Basnight; S R Patel; S C Patel; W Wiese
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

4.  Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.

Authors:  W W Hauck; T Hyslop; M L Chen; R Patnaik; R L Williams
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

5.  Reporting of numerical and statistical differences in abstracts: improving but not optimal.

Authors:  Eric Dryver; Janet E Hux
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

6.  Efficacy of an enzyme-linked immunosorbent assay for detection of urinary tract immunoglobulins for diagnosis of urinary tract infections.

Authors:  J A Kellogg; J P Manzella; J W Seiple; S J Fortna; J W Cook; J S Levisky
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Endoscopic local injection of ethanolamine oleate and thrombin as an effective treatment for bleeding duodenal ulcer: a controlled trial.

Authors:  M Moretó; M Zaballa; M J Suárez; S Ibáñez; E Ojembarrena; J M Castillo
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

Review 8.  Clinical trials and clinical practice in the elderly. A focus on hypertension.

Authors:  M E Kitler
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

9.  Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.

Authors:  Francesco Recchia; Giampiero Candeloro; Alisia Cesta; Mario DI Staso; Pierluigi Bonfili; Giovanni Luca Gravina; Ernesto DI Cesare; Stefano Necozione; Silvio Rea
Journal:  Mol Clin Oncol       Date:  2014-03-21

10.  Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension.

Authors:  E J Pérez-Stable; T J Coates; R B Baron; B S Biró; W W Hauck; K S McHenry; P S Gardiner; D Feigal
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.